The prevention and treatment of radiotherapy-induced xerostomia

Seminars in Radiation Oncology

Volumn 13, Issue 3, 2003, Pages 302-308

  Eisbruch, Avraham ^a   Rhodus, Nelson ^b   Rosenthal, David ^b   Murphy, Barbara ^b   Rasch, Coen ^b   Sonis, Stephen ^b   Scarantino, Charles ^b   Brizel, David ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANCITABINE; ETHIOL; PILOCARPINE;

CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DIAPHORESIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; INJECTION PAIN; NAUSEA; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; RHINITIS; SALIVATION; SIDE EFFECT; SKIN TOXICITY; TREATMENT PLANNING; XEROSTOMIA;

EID: 0042026872     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(03)00027-4     Document Type: Conference Paper

References (52)

1. Eisbruch A, Rhodus N, Rosenthal D, et al: How should we measure and report xerostomia? Semin Radiat Oncol 13:226-234, 2003
2. Levine MJ, Aguirre A, Hatton HN, et al: Artificial saliva. J Dent Res 66:693-698, 1987
3. Olsson H, Axell T: Objective and subjective efficacy of saliva substitutes containing mucin and carboxymethyl cellulose. Scand J Dent Res 99:316-319, 1999
4. Jellema PA, Langendijk H, Bergenhenegouwen L: The efficacy of Xialine in patients with xerostomia resulting from radiotherapy of head and neck cancer. Radiother Oncol 59:157-160, 2001
5. Curry RC, Patey DH: A clinical test for parotid function. Br J Surg 51:891-892, 1964
6. LeVeque FG, Montgomery M, Potter D: A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11:1124-1131, 1993
7. Johnson JT, Ferretti GA, Nethery WJ: Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329:390-395, 1993
8. Horiot JC, Lipinski F, Schraub S, et al: Post-radiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study. Radiother Oncol 55:233-239, 2000
9. Jonstone PAS, Peng YP, May BC, et al: Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 50:353-357, 2001
10. Fontanesi J, Golden EB, Cianci P: Hyperbaric oxygen therapy can reverse radiation-induced xerostomia. J Hyperbaric Med 6:215-221, 1991
11. Kim KG, Kim JY, Sung MW, et al: The effect of pilocarpin and atropin administration on radiation-induced injury of rat submandibular gland. Acta Otolaryngol 111:967-973, 1991
12. Coppes RP, Zeilstra LJW, Vissink A, et al: Sialogogue-related radioprotection of salivary gland function: The degranulation concept revisited. Radiat Res 148:240-247, 1997
13. Valdez IH, Wolff A, Atkinson JC, et al: Use of pilocarpin during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 71:1848-1851, 1993
14. Zimmerman RP, Mark RJ, Tran LM, et al: Concomitant pilocarpin during head and neck irradiation is associated with decreased posttreatment xerostomia. Int J Radiat Oncol Biol Phys 37:571-575, 1997
15. Scarantino C, Leveque F, Scott C, et al: A phase III study to test the efficacy of the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with curative radiation therapy of head and neck cancer patients: RTOG 9709. Int J Radiat Oncol Biol Phys (in press)
16. Warde P, Osullivan B, Aslanidis J, et al: A phase III placebo-controlled trial of oral pilocarpin in patients undergoing radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 54:9-13, 2002
17. Hassan SJ, Weymuller EA: Assessment of quality of life in head and neck cancer patients. Head Neck 15:485-496, 1993
18. Nagler RM, Laufer D: Protection against irradiation-induced damage to salivary glands by adrenergic agonist administration. Int J Radiat Oncol Biol Phys 40:477-81, 1998
19. Schuchter LM, Luginbuhl WE, Mergot NT: Current status of toxicity protectants in cancer therapy. Semin Oncol 19:742-749, 1992
20. Sodicoff M, Conger AD, Pratt NE, et al: Radioprotection by WR-2721 against long-term chronic damage in the rat parotid gland. Radiat Res 76:172-179, 1978
21. McDonald S, Meyerowitz C, Smudzin T, et al: Preliminary results of a pilot study using WR-2721 before fractionated radiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 29:747-754, 1994
22. Bohuslavizki KH, Klutman S, Brenner W, et al: Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo controlled study. J Clin Oncol 16:3542-3549, 1998
23. Rudat V, Meyer J, Momm F, et al: Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys 48:1339-1343, 2000
24. Buntzel J, Kutner K, Frohlich D, et al: Selective cytoprotection with amifostine in concurrent chemoradiotherapy for head and neck cancer. Ann Oncol 9:505-509, 1998
25. Bourhis J, De Crevoisier R, Abdulkarim B, et al: A randomized study of very accelerated radiotherapy with of without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 46:1105-1108, 2000
26. Buntzel J, Glatzel M, Kuttner K, et al: Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 12:4-13, 2002 (suppl 1)
27. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J. Clin Oncol 18:339-3345, 2000
28. Shaw LM, Bonner HS, Schuchter L, et al: Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 26:34-36, 1999
29. Koukurakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
30. Rani P, Curran J: A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 12:18-19, 2002 (suppl 1)
31. O'Connell AC, Baccaglini L, Fox PC, et al: safety and efficacy of adenovirus-mediated transfer of the human aquaporin-1 cDNA to irradiated parotid glands of nonhuman primates. Cancer Gene Ther 6:505-513, 1999
32. Hazuka MB, Martel MK, Marsh L, et al: Preservation of parotid function after external beam irradiation in head and neck cancer patients: A feasibility study using 3-dimensional treatment planning. Int J Radiat Oncol Biol Phys 27:731-737, 1993
33. O'Sullivan B, Warde P, Grice B, et al: The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 51:332-343, 2001
34. Eisbruch A, Ship JA, Martel MK, et al: Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results. Int J Radiat Oncol Biol Phys 36:469-480, 1996
35. Maes A, Weltens C, Flamen P, et al: Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol 63:203-211, 2002
36. Eisbruch A, Marsh LH, Martel MK, et al: Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing. Int J Radiat Oncol Biol Phys 41:559-568, 1998
37. Butler EB, The BS, Grant WS, et al: SMART (simultaneous modulated accelerated radiation therapy) boost: A new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 45:21-32, 1999
38. Wu Q, Manning M, Schmidt-Ullrich R, et al: The potential for sparing of parotids and escalation of biologically equivalent dose with intensity modulated radiation treatments of head and neck cancers: A treatment design study. Int J Radiat Oncol Biol Phys 46:195-205, 2000
39. Chao KSC, Low D, Perez CA, et al: Intensity-modulated radiation therapy in head and neck cancer: The Mallincrodt experience. Int J Cancer 90:92-103, 2000
40. Hunt MA, Zelefsky MJ, Wolden S, et al: Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 49:623-632, 2001
41. De Neve W, De Gersem W, Derycke S: Clinical delivery of IMRT for relapsed or second-primary head and neck cancer using a multileaf collimator with dynamic control. Radiother Oncol 50:301-314, 1999
42. Lee N, Xia P, Quivey JM, et al: Intensity modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:12-22, 2002
43. Vineberg KA, Eisbruch A, Coselmon MM, et al: Is uniform target dose possible in IMRT plans in the head and neck? Int J Radiat Oncol Biol Phys 52:1159-1172, 2002
44. Eisbruch A, Ship JA, Kim HM, et al: Partial irradiation of the parotid gland. Semin Radiat Oncol 11:234-239, 2001
45. Chao KSC, Majhail N, Huang CJ, et al: Intensity modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. Radiother Oncol 61:275-280, 2001
46. Malouf JG, Aragon C, Eisbruch A, et al. Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. Cancer Control Prevent (in press)
47. Osoba D, Rodrigues G, Myles J, et al: Interpretation of the significance of changes in health-related quality of life scores. J Clin Oncol 16:139-144, 1998
48. Eisbruch A, Kim HM, Terrell JE, et al: Xerostomia and its predictors following parotid-sparing irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 50:695-704, 2001
49. Milne RW, Dawes C: The relative contribution of different salivary glands to the blood group activity of whole saliva in humans. Vox Sang 25:298-307, 1973
50. Greer.JE, Eltorky M, Robbins KT: A feasibility study of salivary gland autograft transplantation for xerostomia. Head Neck 22:241-6, 2000
51. Jha N, Seikaly H, Mcgaw T, et al: Submandibular salivary gland transfer prevents radiation-induced xerostomia. Int J Radiat Oncol Biol Phys 46:7-11, 2000
52. Roesink JM, Konings AW, Terhaard CH, et al: Preservation of the rat parotid gland function after radiation by prophylactic pilocarpin treatment: Radiation dose dependency and compensatory mechanisms. Int J Radiat Oncol Biol Phys 45:483-489, 1999